Header: There's video-on-demand for the August 20, 2024, multi-panelist webinar from Decibio, on the future of NGS, centralized, decentralized, or too complex to call.
###
Decibio sponsored an all-star panel discussing the future of centralized and decentralized NGS, and it's archived in the cloud, viewable with email registration. (In the process you'll also be given a second step to quickly request a copy of the 6-slide deck that was used.)
What to Expect:
- Presentation: Key findings on market structures in NGS
- Panel Discussion: Insights from top experts in the industry
- Q&A Session: Your chance to ask questions and engage with the panel
Speakers:
- George Daneker Jr. MD, Chief Clinical Officer, GM of Oncology at Myriad
- Vik Vaz, Head of Strategy, Market Intelligence at Illumina
- David Westenberg, Managing Director, Equity Research at Piper Sandler
- Amber Leigh, Amber Leigh Consulting
- Jerome Madison, Vice President of Product Management at Labcorp
- Shawn Levy, Chief Science Officer at Element Biosciences
I don't want to flag the conclusions in advance, but here are 8 quick takeaways as offered by Chat GPT after it watched the seminar.
- Centralized labs excel in complex testing and economies of scale.
- Decentralized labs offer faster results, enhancing patient care access.
- Regulatory and cost challenges hinder decentralized NGS adoption.
- Reimbursement for decentralized MRD testing remains uncertain and complex.
- Liquid biopsy fills gaps where tissue samples are inadequate.
- Universal germline testing could improve early detection and prevention.
- Multi-omics expands biological insights but adds complexity.
- The future likely combines centralized and decentralized NGS models.
AI Tip!
After Chat GPT gave its initial 8 bullets, I asked it to try to put them in a better order [shown above].
AI Humor!
See takeaways expressed "in a verbose and confusing style," and a review of the webinar by comedian Lewis Black - sidebar here.
